Oracea set to generate $260m sales in 2011

Written by on September 8, 2011 in Oracea (40mg doxycycline), patents with 0 Comments

An interesting note from the detailed interim judgement in the ongoing patent dispute between Galderma and Mylan.

As part of the proceedings Mylan looked at the on-going Oracea sales and projected that Galderma can expect to receive around $260 million in 2011.

MYLAN PHARMACEUTICALS INC., v.  GALDERMA LABORATORIES, L.P.; et. al.

Mylan projected that Oracea’s brand dollars for the period of January 2011  through December 2011  would be approximately $258.1  million.

Oracea’s sales growth was listed as

  • 2007: $43 million
  • 2008: $80.4 million
  • 2009: $155.3 million
  • 2010: $236.7 million
  • 2013: 319 million [updated]

Obviously a highly successful product for Galderma.

As I noted recently, the battle still has some way to go. As neither Galderma nor Mylan prevailed with all of their claims, further arguments are required from each party.

[update]: Oracea sales $319m y/e March 2013

Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.